China · Delayed Price · Currency is CNY Guobang Pharma Statistics
Total Valuation
Guobang Pharma has a market cap or net worth of CNY 14.28 billion. The enterprise value is 12.57 billion.
| Market Cap | 14.28B |
| Enterprise Value | 12.57B |
Important Dates
The last earnings date was Saturday, March 28, 2026.
| Earnings Date | Mar 28, 2026 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
Guobang Pharma has 552.99 million shares outstanding. The number of shares has decreased by -0.66% in one year.
| Current Share Class | 552.99M |
| Shares Outstanding | 552.99M |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | +1.10% |
| Owned by Insiders (%) | 12.79% |
| Owned by Institutions (%) | 15.61% |
| Float | 225.70M |
Valuation Ratios
The trailing PE ratio is 17.45.
| PE Ratio | 17.45 |
| Forward PE | n/a |
| PS Ratio | 2.38 |
| PB Ratio | 1.67 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | 50.71 |
| P/OCF Ratio | 25.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.73, with an EV/FCF ratio of 44.64.
| EV / Earnings | 15.31 |
| EV / Sales | 2.09 |
| EV / EBITDA | 8.73 |
| EV / EBIT | 13.07 |
| EV / FCF | 44.64 |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.18 |
| Quick Ratio | 2.14 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 3.52 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.85% and return on invested capital (ROIC) is 11.92%.
| Return on Equity (ROE) | 9.85% |
| Return on Assets (ROA) | 5.52% |
| Return on Invested Capital (ROIC) | 11.92% |
| Return on Capital Employed (ROCE) | 10.61% |
| Weighted Average Cost of Capital (WACC) | 6.10% |
| Revenue Per Employee | 1.50M |
| Profits Per Employee | 205,051 |
| Employee Count | 4,003 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.83 |
Taxes
In the past 12 months, Guobang Pharma has paid 133.69 million in taxes.
| Income Tax | 133.69M |
| Effective Tax Rate | 14.05% |
Stock Price Statistics
The stock price has increased by +33.25% in the last 52 weeks. The beta is 0.41, so Guobang Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +33.25% |
| 50-Day Moving Average | 26.98 |
| 200-Day Moving Average | 23.78 |
| Relative Strength Index (RSI) | 43.70 |
| Average Volume (20 Days) | 4,599,688 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guobang Pharma had revenue of CNY 6.01 billion and earned 820.82 million in profits. Earnings per share was 1.48.
| Revenue | 6.01B |
| Gross Profit | 1.56B |
| Operating Income | 961.88M |
| Pretax Income | 951.26M |
| Net Income | 820.82M |
| EBITDA | 1.44B |
| EBIT | 961.88M |
| Earnings Per Share (EPS) | 1.48 |
Balance Sheet
The company has 2.70 billion in cash and 991.41 million in debt, with a net cash position of 1.71 billion or 3.10 per share.
| Cash & Cash Equivalents | 2.70B |
| Total Debt | 991.41M |
| Net Cash | 1.71B |
| Net Cash Per Share | 3.10 |
| Equity (Book Value) | 8.56B |
| Book Value Per Share | 15.36 |
| Working Capital | 4.19B |
Cash Flow
In the last 12 months, operating cash flow was 559.28 million and capital expenditures -277.71 million, giving a free cash flow of 281.57 million.
| Operating Cash Flow | 559.28M |
| Capital Expenditures | -277.71M |
| Depreciation & Amortization | 477.62M |
| Net Borrowing | 218.24M |
| Free Cash Flow | 281.57M |
| FCF Per Share | 0.51 |
Margins
Gross margin is 26.03%, with operating and profit margins of 16.00% and 13.65%.
| Gross Margin | 26.03% |
| Operating Margin | 16.00% |
| Pretax Margin | 15.82% |
| Profit Margin | 13.65% |
| EBITDA Margin | 23.95% |
| EBIT Margin | 16.00% |
| FCF Margin | 4.68% |
Dividends & Yields
This stock pays an annual dividend of 0.61, which amounts to a dividend yield of 2.38%.
| Dividend Per Share | 0.61 |
| Dividend Yield | 2.38% |
| Dividend Growth (YoY) | 100.92% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 43.81% |
| Buyback Yield | 0.66% |
| Shareholder Yield | 3.04% |
| Earnings Yield | 5.75% |
| FCF Yield | 1.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |